Edition:
United States

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

125.80SEK
14 Dec 2018
Change (% chg)

-1.80kr (-1.41%)
Prev Close
127.60kr
Open
127.60kr
Day's High
127.60kr
Day's Low
124.40kr
Volume
130,472
Avg. Vol
140,940
52-wk High
168.00kr
52-wk Low
82.80kr

Latest Key Developments (Source: Significant Developments)

Recipharm CEO Sells 1.6 Mln Shares, Representing About 12.7 Pct Stake
Friday, 16 Nov 2018 01:45am EST 

Nov 16 (Reuters) - Recipharm AB (publ) ::RECIPHARM CEO SELLS SHARES - REMAINS COMMITTED AND SIGNIFICANT HOLDER.RECIPHARM - THOMAS ELDERED, CEO AND CO-FOUNDER OF RECIPHARM AB, HAS INFORMED COMPANY THAT HE HAS SOLD 1,559,125 CLASS B SHARES IN RECIPHARM.THOMAS ELDERED INFORMED CO HE SOLD 1,559,125 CLASS B SHARES REPRESENTING ABOUT 12.7% OF HIS TOTAL SHAREHOLDING IN CO.FOLLOWING TRANSACTION, THOMAS ELDERED REMAINS SINGLE LARGEST SHAREHOLDER IN RECIPHARM.THOMAS ELDERED HOLDS 15.8% OF SHARES AND 38.7% OF VOTES IN COMPANY.RECIPHARM - THOMAS ELDERED SOLD SHARES IN RECIPHARM, REPRESENTING ABOUT 12.7% OF HIS TOTAL SHAREHOLDING IN CO, TO SWEDISH INSTITUTIONAL INVESTOR.  Full Article

Recipharm Q3 EBITDA Up At SEK 151 Million
Thursday, 8 Nov 2018 01:45am EST 

Nov 8 (Reuters) - Recipharm AB (publ) ::Q3 EBITDA SEK 151 MILLION VERSUS SEK 103 MILLION YEAR AGO.Q3 NET SALES SEK 1.42 BILLION VERSUS SEK 1.20 BILLION YEAR AGO.  Full Article

Recipharm Q1 EBITDA Up At SEK 250 Million
Friday, 27 Apr 2018 01:45am EDT 

April 27 (Reuters) - RECIPHARM AB (PUBL) ::Q1 EBITDA SEK 250 MILLION VERSUS SEK 159 MILLION YEAR AGO.Q1 NET SALES SEK 1.51 BILLION VERSUS SEK 1.33 BILLION YEAR AGO.JAN-MARCH OPERATING PROFIT (EBIT) AMOUNTED TO SEK 120 MILLION (46).  Full Article

Recipharm Signs Licensing Agreement with Altus Formulation
Monday, 5 Mar 2018 04:00am EST 

March 5 (Reuters) - RECIPHARM AB (PUBL) ::RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES.‍HAS SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC​.‍SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC.​.‍ WILL CO-DEVELOP NEW VALUE ADDED MEDICINES FOR ITS CUSTOMERS UTILISING ALTUS' PATENTED INTELLITAB™ AND FLEXITAB™ DRUG DELIVERY TECHNOLOGIES.​.  Full Article

Recipharm CFO Resigns
Monday, 26 Feb 2018 02:05am EST 

Feb 26 (Reuters) - RECIPHARM AB (PUBL) ::CHIEF FINANCIAL OFFICER TO LEAVE RECIPHARM.CFO HENRIK STENQVIST HAS RESIGNED FROM HIS POSITION.‍HENRIK STENQVIST WILL SERVE AS CFO UNTIL LATER IN SPRING.​.SEARCH PROCESS HAS COMMENCED TO APPOINT A NEW CFO..  Full Article

Recipharm Q4 EBITDA At SEK 226 Million
Thursday, 22 Feb 2018 01:45am EST 

Feb 22 (Reuters) - RECIPHARM AB (PUBL) ::Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO.Q4 EBITDA SEK 226 MILLION VERSUS SEK 229 MILLION YEAR AGO.PROPOSES NO DIVIDEND FOR 2017.  Full Article

Recipharm Buys Remaining Shares In Nitin Lifesciences
Tuesday, 2 Jan 2018 02:30am EST 

Jan 2 (Reuters) - Recipharm Ab (Publ) ::RECIPHARM ACQUIRES REMAINING SHARES IN NITIN LIFESCIENCES LTD.RECIPHARM AB (PUBL) - CONSIDERATION IS INR 2,800 MILLION (SEK 351 MILLION1).RECIPHARM AB (PUBL) - REACHED AN AGREEMENT TO ACQUIRE REMAINING 26 PER CENT OF SHARES OF NITIN LIFESCIENCES LIMITED.RECIPHARM AB (PUBL) - INR 600 MILLION (SEK 75 MILLION1) WILL BE PAID IN NEWLY ISSUED RECIPHARM SHARES (RECI-B).  Full Article

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 01:45am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.Q3 NET SALES SEK ‍1.20​ BILLION VERSUS SEK 1.14 BILLION YEAR AGO.  Full Article

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 01:45am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) :Q3 NET SALES SEK ‍1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO.Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.  Full Article

Recipharm to end operations in two facilities in Sweden
Thursday, 9 Nov 2017 01:44am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::RECIPHARM TO END OPERATIONS IN TWO FACILITIES IN SWEDEN.‍TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES DURING SECOND HALF OF 2019​.SAYS ‍WILL EVALUATE DIFFERENT OPTIONS FOR FACILITY SUCH AS DIVESTMENT OF MANUFACTURING SITE​.‍FINAL DECISION REGARDING DISCONTINUED MANUFACTURING OPERATIONS IN STOCKHOLM AND HÖGANÄS TO BE MADE BEFORE END-2017.‍CLOSURE AFFECTS APPROXIMATELY 225 OF SWEDISH EMPLOYEES​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES IN GREATER STOCKHOLM AREA DURING SECOND HALF OF 2019​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO DISCONTINUE OPERATIONS ARE EXPECTED TO BE CHARGED TO Q4​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO BE CHARGED TO Q4 RESULTS​.  Full Article